Key facts
- Curve (Specialty Chemicals)’s last known valuation is $4.0M (Mar 2025).
- It has raised $1.7M; the latest was Early Stage VC ($3.5M) in Oct 2026.
- Notable investors include Hatcher+, Stockholm Innovation & Growth, 8+ Ventures, Brinc (Private Equity), Erik Rosengren — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Curve (Specialty Chemicals)
- ·The full record, as it builds
Funding rounds
No funding rounds for Curve (Specialty Chemicals) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Curve (Specialty Chemicals)
Developer of protein biomanufacturing technology designed to support scalable and cost-efficient production for large-volume industries. The company offers a modular production architecture that replaces traditional bioreactors and integrates hardware, biology, and real-time data, enabling organizations in food, ingredients, materials, and related sectors to manufacture proteins with improved economic efficiency.
- Sector
- Materials and Resources
- HQ
- Malmö, Sweden
- Founded
- 2022
- Employees
- 10
- Website
- curvebio.tech/
- Ownership
- Privately Held (backing)
Curve (Specialty Chemicals) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Curve (Specialty Chemicals) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Curve (Specialty Chemicals) in its N-PORT filings yet. We sweep new filings monthly.